bioAffinity Technologies (BIAF) Proxy Filing summary

Executive summary

• Special Meeting scheduled for October 2, 2024, to vote on key proposals related to recent financing transactions and warrant exercises.

• Focus on advancing noninvasive lung cancer diagnostics and leveraging new capital for operational growth.

• Board and management express gratitude for shareholder support and emphasize the importance of voting.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of up to 1,801,944 shares of common stock upon exercise of warrants from recent offerings and inducement transactions.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.

• Board recommends voting FOR both proposals.

• Stockholders as of August 30, 2024, are eligible to vote; each share has one vote.

Board of directors and corporate governance

• Board is actively soliciting proxies and will pay all solicitation costs.

• Inspectors of election will tabulate and certify votes at the meeting.

• Certain stockholders holding over 16% of shares have entered into a Support Agreement to vote in favor of the warrant exercise proposal.